Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Post by TheShedCFCon Jun 02, 2020 8:12pm

147 Views

Post# 31104222

Leave if you’re bashing the stock

I get bashing people and naming names.....but if you’re bashing the stock you should respectfully GTFO
We don’t want or need you.....and for the posters (you know who you are) that post the junk that gets people so infuriated.....you should just stop stoking the fire.....you’re ruining the experience for all the good guys
This is a messaging board for sharing theories and real information......thankfully the smart and intelligent posters far outweigh the dummies.....that’s the only reason why I’m still here.

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity